CIC
What's Inside


College Links

 About

 Directory

 Employment

 Map/Directions

 Volunteer

Search

 

 

Make a Gift box


 

 
  Home > Current Clinical Trials > Small Animal Surgery
 

Small Animal Surgery

CVMVMC2 - image - 690x350 - lake dog

Welcome to the Small Animal Surgery Studies Page!

If you would like more information about a study, or think you would like to enroll your pet, contact the person listed under the study. You may also Contact Us at the CIC.

Currently open studies:
1. A randomized, placebo-controlled trial to investigate the safety and efficacy or an oral nutraceutical for the treatment of arthritis in client-owned dogs

2. A pilot study to evaluate the effectiveness, safety and acceptability of study drug for the control of pain and inflammation associated with osteoarthritis in dogs under clinical conditions 

3. Evaluation of Gabapentin in the Post-Operative Management of Pain following TPLO Surgery in Dogs 

A randomized, placebo-controlled trial to investigate the safety and efficacy or an oral nutraceutical for the treatment of arthritis in client-owned dogs

Current Status: Open and enrolling
Principal Investigator: Michael Conzemius, DVM, PhD, DACVS
Contact: Sara Pracht, study technician, at 612-626-3574, prach011@umn.edu

Arthritis is a common problem in the dog and often decreases quality of life. One treatment option often recommended by veterinarians for treating the signs of arthritis is a food supplement called a nutraceutical. The purpose of this study is to test if a new nutraceutical is safe and effective for the treatment of arthritis in the dog. Nutraceuticals are not considered drugs by the FDA and are generally felt to be safe. This is a three group, placebo-controlled study, meaning your dog could receive placebo, a control nutraceutical (Dasuquin®) or the new nutraceutical. The study is also double-blind, meaning neither the owner nor Dr. Conzemius will know which treatment a dog is on until the conclusion of the study.

We are looking for dogs with:

  • obvious lameness and pain
  • not on any pain medications or other nutraceuticals (such as steroids, glucosamine/chondroitin, certain foods)

There are several visits to the study:

  • Enrollment - exam, radiographs to confirm osteoarthritis (OA), blood sampling, and fitting with an accelerometer on a special collar. The dog will wear this collar throughout the study.
  • Day 7 - Recheck to collect accelerometer data and to receive study treatment (placebo, Dasuquin or new nutraceutical). Owners will give tablets at home.
  • Day 30 - Visit to the VMC for exam, complete pain inventory and for us to collect accelerometer data. Study treatment will be refilled.
  • Day 60 - Visit to the VMC for exam, complete pain inventory and for us to collect accelerometer data. Study treatment will be refilled.
  • Day 90 - Final visit to the VMC for exam, complete pain inventory and for us to collect accelerometer data. Owners return any unused tablets at this time.

This study covers costs of all procedures listed above, plus $300 at the conclusion.

If you are interested in participating or in referring a dog for this study, please contact Sara Pracht above.

Return to top


A pilot study to evaluate the effectiveness, safety and acceptability of study drug for the control of pain and inflammation associated with osteoarthritis in dogs under clinical conditions.

Current Status: Open and enrolling
Principal Investigator: Michael Conzemius, DVM, PhD, DACVS
Contact:
Sara Pracht, study technician, at 612-626-3574, prach011@umn.edu

 
This is a placebo-controlled, double-blinded study to evaluate a new non-steroidal anti-inflammatory drug (NSAID) in a tablet form. Dogs will receive either the study drug or placebo once daily for 28 days. Double–blinded means that neither the study staff seeing the dogs nor the owners will know which treatment the dog is on. We will measure how lame the dogs are by exam, standard lameness checks, and by gait analysis on a force plate. Study visits include two baseline visits a week or less apart, follow up visits at Day 14 and Day 28. Owners will give the tablets at home and will keep records for us. It will be important that the same owner do this for the month of the study.

All study procedures are provided at no charge and owners who complete the study will receive an additional $300 for their time and trouble. 

We are looking for dogs which have:
  • Osteoarthritis (OA) OA observed in the shoulder, elbow, hip or stifle joint (knee) for at least 3 weeks (presence of OA will need to be confirmed by exam and X-ray at the first visit
  • Other than OA, no neurological or musculoskeletal disorders, chronic pain, or systemic disease that could interfere with the goals of the study
  • No recent surgery on any joint
  • No recent injury to the joint and does not show sigs of cranial cruciate rupture

We will evaluate other criteria at the baseline visits.

Certain medications need to be stopped prior to the study (NSAIDS, corticosteroids, opioids, and others. Please ask about this when calling us.

For more information, please call or email Sara Pracht above.

Return to top


Evaluation of Gabapentin in the Post-Operative Management of Pain Following TPLO Surgery in Dogs
 

Current Status: Open and enrolling
Investigators:
Michael Conzemius, DVM, PhD, DACVS
Daniel Almeida, DVM, MS
Erin Wendt-Hornickle, DVM, DACVAA
Contact: Andrea Eckert, study technician, at 612-625-3157, aleckert@umn.edu

Managing pain after surgery continues to be of increasing importance in veterinary medicine. Gabapentin has been used for pain management during and after surgery.  Previous studies indicate that the frequency of dosing may be essential to maintaining a level of pain management but this has not been verified by clinical trials. This study will evaluate the effectiveness of gabapentin added to standard of care in post-operative pain management as compared to standard of care alone following TPLO (tiblial plateau leveling osteotomy) surgery in dogs.

We are looking for healthy adult dogs with a cranial cruciate ligament rupture in one leg scheduled for TPLO surgery at the Veterinary Medical Center (VMC). Dogs will weigh 33 lbs or more, with no signficant abnormalities on bloodwork and urinalysis. Patients will not have received steroids, gabapentin or tramadol for 3 days and no aspirin for 7 days prior to participation.

Dogs will be randomly chosen to receive either standard of care (carprofen and hydromorphone) alone or gabapentin plus standard of care. Medications will begin the night before surgery. We will perform computer-aided pressure platform stance analysis once before surgery and once per day for 3 days after surgery. Dogs will need to stay through this third day.

There is one final recheck at 14 days post-surgery.

Costs of the 3 day hospitalization in the VMC, carprofen, hydromorphone, gabapentin, and pressure stance analysis will be covered by the study. The costs of the presurgical exam, baseline blood work, radiographs and TPLO surgery will be paid by the owner. All owners will receive a $300 credit in addition to help offset these costs.

Return to top

  

 

 

Notice of Privacy Practices